All In Biotech

NDA 019658 · Bayer Healthcare LLC

Claritin

Loratadine · Oral

Novel

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1993

Apr 12, 1993

Approved uses

4

Original approval plus efficacy supplements

Registered trials

89

27 Phase 3, 6 recruiting

FAERS reports

103,057

49,212 serious, 4,538 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 5, 2025.

Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose itchy, watery eyes sneezing itching of the nose or throat

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 19, 2003 Supplement 20 · Efficacy Letter
  • Nov 27, 2002 Supplement 18 · Efficacy LetterReview
  • Sep 20, 1995 Supplement 3 · Efficacy
  • Apr 12, 1993 Original approval · Type 1 - New Molecular Entity
2 products under this application
  • CLARITIN · LORATADINE 10MG · TABLET, ORAL · Over-the-counter
  • CLARITIN HIVES RELIEF · LORATADINE 10MG · TABLET, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Loratadine" as an intervention, any sponsor and status, largest first.

All 89 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective11,854
  • fatigue6,591
  • nausea5,790
  • headache5,304
  • dyspnoea4,791
  • diarrhoea4,780
  • off label use4,567
  • dizziness4,289
  • pain4,055
  • rash3,368
  • pruritus3,350
  • cough3,083

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004965
20051,071
20061,067
2007939
20081,073
20091,316
20101,637
20112,020
20123,015
20133,959
20144,683
20157,017
20168,555
20178,774
20187,746
20197,819
20207,024
20216,285
20226,083
20235,477
20245,990
20255,930
20264,611

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 391 on PubMed

Sponsor: Bayer · Also marketed as Claritin Hives Relief

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.